Proteomic studies on protein modification by cyclopentenone prostaglandins: Expanding our view on electrophile actions

被引:32
作者
Garzon, Beatriz [1 ]
Oeste, Clara L. [1 ]
Diez-Dacal, Beatriz [1 ]
Perez-Sala, Dolores [1 ]
机构
[1] CSIC, Ctr Invest Biol, Chem & Phys Biol Dept, Madrid 28040, Spain
关键词
Cyclopentenone prostaglandins; Posttranslational modification; Ras proteins; Proteomics 15-deoxy-Delta 12,14-prostaglandin J2; Inflammation and tumorigenesis; ACTIVATED RECEPTOR-GAMMA; FACTOR-KAPPA-B; BREAST-CANCER CELLS; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); COVALENT MODIFICATION; DNA-BINDING; ENDOGENOUS ELECTROPHILE; BIOLOGICAL-ACTIVITIES; MESANGIAL CELLS; DOWN-REGULATION;
D O I
10.1016/j.jprot.2011.03.028
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Cyclopentenone prostaglandins (cyPG) are lipid mediators that participate in the mechanisms regulating inflammation and tumorigenesis. cyPG are electrophilic compounds that act mainly through the covalent modification of cellular proteins. The stability of many cyPG-protein adducts makes them suitable for proteomic analysis. Indeed, methodological advances in recent years have allowed identifying many cyPG targets, including components of pro-inflammatory transcription factors, cytoskeletal proteins, signaling kinases and proteins involved in redox control. Insight into the diversity of cyPG targets is providing a better understanding of their mechanism of action, uncovering novel links between resolution of inflammation, proliferation and redox regulation. Moreover, identification of the target residues has unveiled the selectivity of protein modification by these electrophiles, providing valuable information for potential pharmacological applications. Among the challenges ahead, the detection of proteins modified by endogenous cyPG and the quantitative aspects of the modification require further efforts. Importantly, only a few years after the appearance of the first proteomic studies, research on cyPG targets is yielding new paradigms for redox and electrophilic signaling. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:2243 / 2263
页数:21
相关论文
共 131 条
[1]   Identification of actin as a 15-deoxy-Δ12,14-prostaglandin J2 target in neuroblastoma cells:: Mass spectrometric, computational, and functional approaches to investigate the effect on cytoskeletal derangement [J].
Aldini, Giancarlo ;
Carini, Marina ;
Vistoli, Giulio ;
Shibata, Takahiro ;
Kusano, Yuri ;
Gamberoni, Luca ;
Dalle-Donne, Isabella ;
Milzani, Aldo ;
Uchida, Koji .
BIOCHEMISTRY, 2007, 46 (10) :2707-2718
[2]   Effects of 15d-PGJ2-loaded poly(D,L-lactide-co-glycolide) nanocapsules on inflammation [J].
Alves, C. F. ;
de Melo, N. F. S. ;
Fraceto, L. F. ;
de Araujo, D. R. ;
Napimoga, M. H. .
BRITISH JOURNAL OF PHARMACOLOGY, 2011, 162 (03) :623-632
[3]   FORMATION OF THIOL CONJUGATES OF 9-DEOXY-DELTA-9,DELTA-12(E)-PROSTAGLANDIN-D2 AND DELTA-12(E)-PROSTAGLANDIN-D2 [J].
ATSMON, J ;
SWEETMAN, BJ ;
BAERTSCHI, SW ;
HARRIS, TM ;
ROBERTS, LJ .
BIOCHEMISTRY, 1990, 29 (15) :3760-3765
[4]   Inflexinol inhibits colon cancer cell growth through inhibition of nuclear factor-κB activity via direct interaction with p50 [J].
Ban, Jung Ok ;
Oh, Ju Hoon ;
Hwang, Bang Yeon ;
Moon, Dong Cheul ;
Jeong, Heon-Sang ;
Lee, Seram ;
Kim, Soyoun ;
Lee, Hyosung ;
Kim, Kyung-Bo ;
Han, Sang Bae ;
Hong, Jin Tae .
MOLECULAR CANCER THERAPEUTICS, 2009, 8 (06) :1613-1624
[5]   Biosynthesis of 15-deoxy-Δ12,14-PGJ2 and the litigation of PPARγ [J].
Bell-Parikh, LC ;
Ide, T ;
Lawson, JA ;
McNamara, P ;
Reilly, M ;
FitzGerald, GA .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (06) :945-955
[6]   Reactions of some cyclopentenones with selected cysteine derivatives and biological activities of the product thioethers [J].
Bickley, JF ;
Ciucci, A ;
Evans, P ;
Roberts, SM ;
Ross, N ;
Santoro, MG .
BIOORGANIC & MEDICINAL CHEMISTRY, 2004, 12 (12) :3221-3227
[7]   Increased plasma levels of 15-deoxy Δ prostaglandin J2 are associated with good outcome in acute atherothrombotic ischemic stroke [J].
Blanco, M ;
Moro, MA ;
Dávalos, A ;
Leira, R ;
Castellanos, M ;
Serena, JN ;
Vivancos, J ;
Rodríguez-Yáñez, M ;
Lizasoain, I ;
Castillo, J .
STROKE, 2005, 36 (06) :1189-1194
[8]   15-deoxy-Δ 12,14-prostaglandin J2 inhibition of NF-κB-DNA binding through covalent modification of the p50 subunit [J].
Cernuda-Morollón, E ;
Pineda-Molina, E ;
Cañada, FJ ;
Pérez-Sala, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (38) :35530-35536
[9]   Redox Regulation of Soluble Epoxide Hydrolase by 15-Deoxy-Δ-Prostaglandin J2 Controls Coronary Hypoxic Vasodilation [J].
Charles, Rebecca L. ;
Burgoyne, Joseph R. ;
Mayr, Manuel ;
Weldon, Steven M. ;
Hubner, Norbert ;
Dong, Hua ;
Morisseau, Christophe ;
Hammock, Bruce D. ;
Landar, Aimee ;
Eaton, Philip .
CIRCULATION RESEARCH, 2011, 108 (03) :324-334
[10]   Induction of apoptosis in estrogen receptor-negative breast cancer cells by natural and synthetic cyclopentenones:: Role of the IκB kinase/nuclear factor-κB pathway [J].
Ciucci, Alessandra ;
Gianferretti, Patrizia ;
Piva, Roberto ;
Guyot, Thierry ;
Snape, Timothy J. ;
Roberts, Stanley M. ;
Santoro, M. Gabriella .
MOLECULAR PHARMACOLOGY, 2006, 70 (05) :1812-1821